The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: An open-label, randomized, phase II study.
 
Naoki Nakamura
No Relationships to Disclose
 
Yuka Kato
Speakers' Bureau - Chugai Pharma
 
Go Makimoto
Honoraria - AstraZeneca Japan; Chugai Pharma
 
Kiichiro Ninomiya
Honoraria - AstraZeneca Japan; Chugai Pharma; Kyowa Kirin; Lilly Japan; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Takeda
 
Daijiro Harada
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Towa Pharmaceutical
Research Funding - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Kissei Pharmaceutical; Lilly; MSD K.K.; Novartis; Pfizer; Takeda
 
Takashi Ninomiya
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma
 
Isao Oze
No Relationships to Disclose
 
Toshio Kubo
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kyowa Kirin; MSD; Nippon Kayaku; Pfizer; Taiho Pharmaceutical; TOWA
 
Masanori Fujii
No Relationships to Disclose
 
Eiki Ichihara
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Novartis; Pfizer; Takeda
Research Funding - Janssen; MSD; Takeda
 
Kadoaki Ohashi
Honoraria - AstraZeneca; Chugai Pharma; MSD
Research Funding - AstraZeneca/MedImmune; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly
 
Toshiyuki Kozuki
Honoraria - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Eisai (Inst); Kyowa-Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Katsuyuki Hotta
Honoraria - AZD; BMS; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD Oncology; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Abbvie; AZD; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD
 
Masahiro Tabata
No Relationships to Disclose
 
Katsuyuki Kiura
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Kyorin (Inst); Merck (Inst); MSD (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)